Molaz Molnupiravir 200 Mg Capsule
Price range: $90.00 through $295.00
| Quantity Value | Price | Quantity | Add To Cart |
|---|---|---|---|
| 120 Capsules | $200.00 |
|
|
| 200 Capsules | $295.00 |
|
|
| 40 Capsules | $90.00 |
|
|
| 80 Capsules | $150.00 |
|
SKU : N/A
Category : Viral Care
Molaz Molnupiravir 200 mg Capsule is an oral antiviral medicine used for treating mild to moderate COVID-19 in adults at high risk of severe disease by reducing viral replication. It works best when started early after symptom onset and must be taken exactly as prescribed.
Molaz Molnupiravir 200 mg Capsule
Molaz Molnupiravir 200 mg Capsule is a prescription antiviral medication developed to help treat mild to moderate coronavirus disease 2019 (COVID-19) in adults who are at risk of developing severe illness, hospitalization, or death. Its active ingredient, molnupiravir, is part of a new class of antiviral agents that interfere with the replication process of the SARS-CoV-2 virus — the pathogen responsible for COVID-19. When used as directed and initiated early in the course of infection, Molaz can help reduce the viral load and contribute to improved clinical outcomes.
What Is Molnupiravir and How It Works
Molnupiravir is a nucleoside analogue antiviral drug. After oral administration, it is rapidly absorbed and metabolized in the body into its active form — N-hydroxycytidine (NHC). The active metabolite is incorporated into the viral RNA by the virus’s own replication enzyme, RNA-dependent RNA polymerase. Once incorporated, it introduces errors into the viral genetic code, leading to what is known as “viral error catastrophe,” which prevents the virus from producing viable new copies of itself. The net effect is a reduction in viral replication, allowing the immune system to clear the infection more efficiently.
Molaz Molnupiravir 200 mg Capsule does not prevent COVID-19 and must be taken only if a positive COVID-19 diagnosis has been confirmed and the patient is at high risk for progression to severe disease. It also is not recommended for severe or hospitalized COVID-19 cases where more aggressive or hospital-based treatments are required.
Indications and Patient Use
Molaz Molnupiravir 200 mg Capsule is indicated for:
-
Adults with mild to moderate COVID-19 confirmed by a positive test
-
Patients at high risk of progressing to severe illness, including those who are older or have underlying health conditions (e.g., diabetes, heart disease, or compromised immunity)
-
Use when other suitable treatment options are not available or appropriate
This capsule is not authorized for prophylaxis (prevention) of COVID-19 and is not recommended for children under 18 due to limited safety data. Likewise, it should be used cautiously in pregnant or breastfeeding individuals, and effective contraception is advised during treatment and for a short period after completion.
Dosage and Administration
The typical treatment regimen for Molaz Molnupiravir 200 mg Capsule involves:
-
Taking 800 mg per dose (equivalent to four 200 mg capsules)
-
Twice daily approximately every 12 hours
-
Over a 5-day course
-
Treatment should begin as soon as possible and within 5 days of symptom onset to maximize benefit
The capsules should be swallowed whole with water and may be taken with or without food. Completion of the full course is critical even if symptoms improve before finishing the medication. Skipping doses or shortening the course can reduce effectiveness.
Benefits of Molaz Molnupiravir Treatment
When used appropriately (especially early in infection), Molaz Molnupiravir 200 mg Capsule can:
-
Reduce the severity of COVID-19 symptoms by lowering viral replication
-
Decrease the risk of progression to severe disease or hospitalization in high-risk adults
-
Provide a convenient oral outpatient therapy compared to intravenous antivirals
-
Allow patients to begin treatment at the first sign of symptomatic infection, improving outcomes
Because it is taken at home under a healthcare provider’s guidance, molnupiravir supports early intervention and can be part of a comprehensive COVID-19 management plan.
Side Effects and Safety Considerations
Common side effects may include:
-
Nausea
-
Diarrhea
-
Headache
-
Dizziness
These symptoms are generally mild and transient. Patients should seek medical advice if side effects persist or worsen. Molnupiravir’s safety profile is still being evaluated, and rare or serious reactions may occur.
Because molnupiravir works by altering viral genetic material, it is not recommended during pregnancy due to potential risks, and women of childbearing potential should use effective contraception during treatment and for at least four days after the last dose. Similarly, men with partners of reproductive potential should consider contraception during treatment and for a short period after.
Common Precautions
-
Not for prevention of COVID-19
-
Not for severe or hospitalized cases
-
Consult a doctor if you have liver, kidney, or immune system disorders
-
Discuss all medications and health conditions before starting
Storage Instructions
Store Molaz Molnupiravir 200 mg Capsules in a cool, dry place away from direct sunlight. Protect from moisture and keep out of reach of children.
External Link for More Information
For detailed, medically reviewed information on molnupiravir, see this Drugs.com resource:
https://www.drugs.com/molnupiravir.html
| Pack Size |
120 Capsules ,200 Capsules ,40 Capsules ,80 Capsules |
|---|
Related products
Artecan 120 mg Injection
Artecan 120 mg Injection is a potent antimalarial medicine containing artesunate used to treat severe malaria caused by Plasmodium falciparum. It works rapidly to reduce parasite load and improve clinical outcomes when administered by a healthcare professional. (WHO – Malaria Treatment Guidelines)
